Intensity Therapeutics, Inc. (INTS) Live Share Price, Invest From India

Intensity Therapeutics, Inc. Stock Performance

as on October 17, 2026 at 2:15 pm IST

Day's Low
Day's High
$3.21
Day's Price Range
$3.38
$3.35
4.18%
Downside
0.90%
Upside
52 Week's Low
52 Week's High
$3.10
52-Week Price Range
$43.50
$3.35
7.55%
Downside
1198.51%
Upside

Intensity Therapeutics, Inc. share price movements today

Previous Close: $3.38
Open: $3.38
Volume: 210.0K
Market Cap: $11.0M
Day's Low - High: $3.21 - $3.38
52 Week Low - High: $3.10 - $43.50

Intensity Therapeutics, Inc. Historical Returns

1 Month Return: -13.66 %
3 Month Return: -29.47 %
1 Year Return: -48.64 %
3 Year Return: -96.61 %
5 Year Return: 0 %

Intensity Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Intensity Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$11.0M

EPS (TTM)

-4.83

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.7

Industry PE ratio

-3.02

PEG Ratio

-0.00

EBITDA

-11.2M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-116.61%

Intensity Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Intensity Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Intensity Therapeutics, Inc.	Buy	$11.0M	NA	-0.70	0.00%	0.00%
Moderna	Neutral	$94.4B	-32.76%	-29.64	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$128.9B	174.93%	29.37	86.04%	0.00%
Regeneron	Buy	$80.1B	42.93%	19.01	84.86%	0.46%

Stock Returns calculator for Intensity Therapeutics, Inc. Stock including INR - Dollar returns

The Intensity Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Intensity Therapeutics, Inc. investment value today

Current value as on today

₹55,502

Returns

-₹44,498

(-44.5%)

Returns from Intensity Therapeutics, Inc. Stock

-₹48,639 (-48.64%)

Dollar Impact

₹4,141 (+4.14%)

Analyst Recommendation on Intensity Therapeutics, Inc. Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for Intensity Therapeutics, Inc.. Average target price of $19.33

Intensity Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Intensity Therapeutics, Inc..

What analysts predicted

82.67%UPSIDE

Target Price

$19.33

Current Price

$3.35

Analyzed by

1 Analysts

High

Target

$19.33

Low

Intensity Therapeutics, Inc. target price $19.33, a slight upside of 82.67% compared to current price of $3.35. According to 1 analysts rating.

Indian Investors' Interest in Intensity Therapeutics, Inc. Stock

Search interest for Intensity Therapeutics, Inc. Stock has decreased by -27% in the last 30 days, reflecting a downward trend in search activity.

Time period: September 19, 2026 to October 19, 2026

Change:-27% versus previous 30 day period

Intensity Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	-	-	-	-	-	-	-	0	0
Operating Income	-4	-5	-3	-3	-3	-2	-2	-3	-2	-3
EBITDA	-4	-4	-3	-3	-3	-2	-2	-3	-2	-3
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	-	0	-	0	0	-	-
Income Before Tax	-4	-4	-3	-3	-3	-2	-2	-3	-2	-3
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-4	-4	-3	-3	-3	-2	-2	-3	-2	-3
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Intensity Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	0	-	0
Operating Income	-5	-6	-8	-7	-8	-16	-11
EBITDA	0	-6	-7	-7	-10	-16	-11
Interest Expense	-	-	0	0	0	-	-
Depreciation	5	-	-	0	0	-	-
Income Before Tax	-5	-6	-7	-7	-10	-16	-11
Income Tax Expense	-	-	-	-	-	-	-
Net Income	-5	-5	-7	-7	-10	-16	-11
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Intensity Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-4	-4	-3	-3	-3	-2	-2	-3	-2	-3
Operating Cash Flow	-4	-4	-3	-2	-1	-2	-2	-2	-1	-2
Investing Cash Flow	3	0	3	-	-	-	-	-	-	-
Financing Cash Flow	0	0	0	2	0	3	7	7	0	1
Change in Cash	-1	-4	0	0	-1	1	4	4	-1	0

Intensity Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-5	-6	-7	-7	-10	-16	-11
Operating Cash Flow	-4	-5	-6	-5	-7	-15	-9
Investing Cash Flow	1	4	-	-	-6	6	-
Financing Cash Flow	3	6	2	2	20	2	18
Change in Cash	1	5	-4	-3	7	-5	9

Global Institutional Holdings in Intensity Therapeutics, Inc.

Check out the Institutions with significant holdings in Intensity Therapeutics, Inc..

Funds	Holdings
Vanguard	0.81%
Fidelity Concord Street Trust	0.52%
VANGUARD INDEX FUNDS	0.52%

Insights on Intensity Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Moderna, Inc. Common Stock has given 153.5% return, outperforming this stock by 250.2%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 738.2% return, outperforming this stock by 786.8%
NEGATIVE IMPACT
Price Dip
In the last 3 years, INTS stock has moved down by -96.7%

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.

Organisation	Intensity Therapeutics, Inc.
Headquarters	1 Enterprise Drive, Shelton, CT, 06484-4779, US
Industry	Biotechnology
CEO	Lewis H. Bender

Key Management of Intensity Therapeutics, Inc.

Name	Title
Mr. James M. Ahlers	Executive Vice President of Corporate Finance
Mr. Lewis H. Bender M.A., M.B.A., M.S.	Founder, President, CEO & Chairman of the Board
Mr. Joseph Talamo CPA, M.B.A.	Chief Financial Officer
Mr. John Wesolowski CPA, M.B.A.	Principal Accounting Officer & Controller

FAQs

What is Intensity Therapeutics, Inc. share price today?

Intensity Therapeutics, Inc. share price today is $3.35 as on October 17, 2026 at 8:45 am IST at the close of the market. Intensity Therapeutics, Inc. share today touched a day high of $3.38 and a low of $3.21.

What is the 52 week high and 52 week low for Intensity Therapeutics, Inc. share?

Intensity Therapeutics, Inc. share touched a 52 week high of $43.50 on October 30, 2025 and a 52 week low of $3.10 on October 13, 2026. Intensity Therapeutics, Inc. stock price today i.e. October 17, 2026 at 8:45 am IST is closed at $3.35,which is 92.30% down from its 52 week high and 8.16% up from its 52 week low.

What is Intensity Therapeutics, Inc.'s market capitalisation today?

Intensity Therapeutics, Inc. market capitalisation is $0.00T as on October 17, 2026 at 8:45 am IST.

How to invest in Intensity Therapeutics, Inc. Stock (INTS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Intensity Therapeutics, Inc. on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Intensity Therapeutics, Inc. Stock (INTS) from India?

Indian investors can start investing in Intensity Therapeutics, Inc. (INTS) shares with as little as ₹94.959999084473 or $1 (as of October 19, 2026 at 5:43 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in Intensity Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on October 19, 2026 at 5:43 am IST). Based on Intensity Therapeutics, Inc. share’s latest price of $3.35 as on October 17, 2026 at 8:45 am IST, you will get 2.9851 shares of Intensity Therapeutics, Inc.. Learn more about fractional shares .